AbbVie reported mixed Q2 2024 results, adding to my concerns of its growth potential. Looking ahead, I see continued pressure for Humira sales and also increasing in-house R&D expenses. These issues ...
I've switched from perpetual growth valuations to exit multiple valuations. HL is being taken private at a P/E ratio of just 18, compared to its ten-year average P/E of 27. On average, Schroders grew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback